glp-1 inflammation drugs calm beyond diabetes and weight loss The Therapeutic Potential of GLP-1
Description
In an ideal world, you would have insurers comparing the burden of covering GLP-1s to the burden of paying for all the other challenges related to long-term chronic disease management
It is possible to have a combination of these different pharmacologies in a unimolecular drug, as GLP-1, GIP, and glucagon all share the same secondary structure as well as a conserved region of amino acids
[DOI] [PubMed] [Google Scholar] 525.Fujitani Y
doi: 10.1007/s10620-012-2353-7
doi: 10.3390/nu12113304
Compare against the established price ranges for retatrutide to identify outliers
